Patents by Inventor Richard DiMarchi

Richard DiMarchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220177538
    Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
    Type: Application
    Filed: July 22, 2021
    Publication date: June 9, 2022
    Inventors: Patrick J. Knerr, Brian Finan, Richard Dimarchi, Lars Linderoth
  • Publication number: 20220125940
    Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
    Type: Application
    Filed: January 12, 2022
    Publication date: April 28, 2022
    Inventors: Patrick James Knerr, Brian Finan, Richard DiMarchi, Lars Linderoth
  • Publication number: 20220000982
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 3, 2019
    Publication date: January 6, 2022
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard Dimarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • Patent number: 10604555
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particularly the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH). The peptides comprise a lysine residue at a position corresponding to position 24 of hGIP(1-31), and comprise a negatively charged modifying group attached to the epsilon amino group of the lysine residue.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 31, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard DiMarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • Publication number: 20190367578
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 3, 2019
    Publication date: December 5, 2019
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard DiMarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • Patent number: 9593155
    Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 14, 2017
    Assignees: MERCK SHARP & DOHME CORP., MSD ITALIA S.R.L., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Paul E. Carrington, George J. Eiermann, Donald J. Marsh, Joseph M. Metzger, Alessandro Pocai, Ranabir Sinha Roy, Elisabetta Bianchi, Paolo Ingallinella, Antonello Pessi, Alessia Santoprete, Elena Capito, Richard Dimarchi, Brian Ward
  • Publication number: 20150307580
    Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
    Type: Application
    Filed: April 14, 2015
    Publication date: October 29, 2015
    Inventors: Paul E. CARRINGTON, George J. EIERMANN, Donald J. MARSH, Joseph M. METZGER, Alessandro POCAI, Ranabir SINHA ROY, Elisabetta BIANCHI, Paolo INGALLINELLA, Antonello PESSI, Alessia PRETE, Elena CAPITO, Richard DIMARCHI, Brian WARD
  • Patent number: 8969294
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: March 3, 2015
    Assignees: Istituto di Recerche di Biologia Molecolare P. Angeletti S.R.L., Indiana University Research and Technology Corporation
    Inventors: Elisabetta Bianchi, Antonello Pessi, Jonathan Day, Richard Dimarchi, David Smiley
  • Publication number: 20140296145
    Abstract: Modified human growth hormone polypeptides and uses thereof are provided.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: AMBRX, INC.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard DiMarchi, Anna-Maria Hays Putnam, Troy Wilson, Bee-Cheng Sim, David Litzinger
  • Publication number: 20130090286
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Application
    Filed: August 6, 2012
    Publication date: April 11, 2013
    Inventors: Elisabetta Bianchi, Antonello Pessi, Jonathan Day, Richard Dimarchi, David Smiley
  • Publication number: 20120165503
    Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
    Type: Application
    Filed: December 18, 2009
    Publication date: June 28, 2012
    Inventors: Paul E. Carrington, George Eiermann, Donald Marsh, Joseph Metzger, Alessandro Pocai, Ranabir Sinha Roy, Bianchi Bianchi, Paolo Ingallinella, Antonello Pessi, Alessia Santoprete, Elena Capito, Richard Dimarchi, Brian Ward
  • Publication number: 20100331246
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Application
    Filed: July 28, 2010
    Publication date: December 30, 2010
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard DIMARCHI, Arnab DE
  • Publication number: 20080108797
    Abstract: Modified human growth hormone polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 8, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung CHO, Thomas DANIEL, Richard DIMARCHI, Anna-Maria HAYS, Troy WILSON, Bee-Cheng SIM, David LITZINGER
  • Publication number: 20080107680
    Abstract: Modified growth hormone polypeptide and uses thereof are provided.
    Type: Application
    Filed: October 25, 2007
    Publication date: May 8, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung Cho, Thomas Daniel, Richard DiMarchi, Anna-Maria Hays, Troy Wilson, Bee-Cheng Sim, David Litzinger
  • Publication number: 20080103294
    Abstract: Modified human growth hormone polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 1, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung CHO, Thomas DANIEL, Richard DIMARCHI, Anna-Maria HAYS, Troy WILSON, Bee-Cheng SIM, David LITZINGER
  • Publication number: 20080102125
    Abstract: Modified growth hormone polypeptide and uses thereof are provided.
    Type: Application
    Filed: October 25, 2007
    Publication date: May 1, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung CHO, Thomas DANIEL, Richard DIMARCHI, Anna-Maria HAYS, Troy WILSON, Bee-Cheng SIM, David LITZINGER
  • Publication number: 20080103293
    Abstract: Modified human growth hormone polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 1, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung CHO, Thomas DANIEL, Richard DIMARCHI, Anna-Maria HAYS, Troy WILSON, Bee-Cheng SIM, David LITZINGER
  • Publication number: 20080102124
    Abstract: Modified growth hormone polypeptide and uses thereof are provided.
    Type: Application
    Filed: October 25, 2007
    Publication date: May 1, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung CHO, Thomas DANIEL, Richard DIMARCHI, Anna-Maria HAYS, Troy WILSON, Bee-Cheng SIM, David LITZINGER
  • Publication number: 20080097083
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 18, 2007
    Publication date: April 24, 2008
    Applicant: AMBRX, INC.
    Inventors: Ho Sung CHO, Thomas DANIEL, Richard DIMARCHI, Anna-Maria HAYS, Troy WILSON, Bee-Cheng SIM, David LITZINGER
  • Publication number: 20070173452
    Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
    Type: Application
    Filed: March 30, 2007
    Publication date: July 26, 2007
    Inventors: Richard DiMarchi, Suad Efendic